奈西立肽在治疗急性失代偿心力衰竭患者中的地位  

Role of Nesiritide in Therapy of Patients with Acute Decompensated Heart Failure

作　　者：胡康新[1] 陈伊[1] 胡佩[1] 

机构地区：[1]南昌市医学科学研究所,江西南昌330001

出　　处：《心血管病学进展》2013年第2期199-203,共5页Advances in Cardiovascular Diseases

摘　　要：柰西立肽为一用重组DNA技术由大肠杆菌制成,具有如心室肌内源性产生的脑利钠肽相同的化学结构和生物学作用。2001年由美国FDA批准的强效扩血管药,最近已用于急性失代偿性心力衰竭患者治疗最新选择。国外文献报道它能短期内改善血流动力学状况和临床症状。在以前研究显示,奈西立肽存在安全性问题,即增高30 d病死率和肾功能损害的危险。最近的意见是,只要我们应用推荐剂量[0.01μg/(kg.min)±负荷剂量],奈西立肽对急性失代偿性心力衰竭患者似乎是安全有效的。现系统复习奈西立肽的一般知识,它在急性失代偿性心力衰竭患者使用的推荐剂量、临床疗效和安全性。Nesiritide（rhBNP） is manufactured from escherichia coli using recombinant DNA technology and has the same chemical structure and biological effects as the BNP produced endogenously by the ventricular myocardium, rhBNP is a potent vasodilator which was approved by US FDA in 2001 for treatment of patients with acute decompensated heart failure（ADHF）. Foreign literatures had showed that rhB- NP may rapidly improve hemodynamic status and clinical symptom of ADHF. In prior study,the safety of rhBNP has been questioned,and rh- BNP was found to increase 30-day mortality and risk for renal impairments. Recent opinion in this regard is that so long as we use recommend dose （0.01μg·kg^-1·min^-1± bolus） rhBNP appear to be safe and effective in patients with ADHF.

关 键 词：奈西立肽 急性失代偿性心力衰竭 推荐剂量 肾功能 30 d病死率 

分 类 号：R541.6[医药卫生—心血管疾病]